Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protalix Biotherapeutics, Inc. on September 8, 2020. The report addresses a specific corporate event regarding the company's stock listing status on the NYSE American.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on regulatory compliance status rather than financial performance.
Material Changes
On September 8, 2020, the Company received notification from the NYSE American LLC that it has regained compliance with all continued listing standards set forth in Part 10 of the NYSE American Company Guide. This resolves a previous non-compliance status.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future operations, or new risk factors. The primary focus is the restoration of listing compliance. A press release dated September 8, 2020, is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the specific listing standards under Part 10 of the NYSE American Company Guide that were previously not met.
- Review the attached press release (Exhibit 99.1) for details on the steps taken to regain compliance.
- Confirm the current trading status of the common stock (Symbol: PLX) on the NYSE American.
- Check subsequent filings for any financial updates or operational milestones not covered in this 8-K.